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Background: Bladder cancer is a common malignancy in Egypt. A history of urinary tract infection can be
considered as a risk factor for bladder cancer. Escherichia coli (E. coli) infection is responsible for 70% of urinary tract
infection. This study aimed to evaluate the role of chronic E. coli infection during bladder carcinogenesis. In order to
achieve this aim, we investigated the histopathological changes in bladder tissue and measured the level of nuclear
factor kappa p65 (NF-κBp65), Bcl-2 and interleukin 6 (IL-6) in four groups each consisting of 25 male albino rats
except of control group consisting of 20 rats. The first group was normal control group, the second group was
infected with E. coli, the third group was administered nitrosamine precursor, and the forth group was infected
with E. coli and administered nitrosamine precursor.
Results: The histopathological examination revealed that E. coli infected group was able alone to produce some
histopathological changes in bladder tissue and that nitrosamine precursor plus E. coli group showed highest
incidences of urinary bladder lesions than the nitrosamine precursor group. NF-κBp65, Bcl-2 and IL-6 levels were
significantly higher in nitrosamine precursor plus E. coli group than the other groups.
Conclusion: These findings suggested that urinary bladder infection by E. coli may play a major additive and
synergistic role during bladder carcinogenesis.
Keywords: Bladder carcinogenesis, E. coli, NF-κBp65, Bcl-2, IL-6Background
Bladder cancer is a common malignancy, worldwide; it
is the seventh most prevalent cancer, accounting for
3.2% of all malignancies [1]. Carcinoma of the bladder is
the most prevalent cancer in Egypt. At the national can-
cer institute, Cairo University, it constitutes 30.3% of all
cancers [2,3]. Nitrate contamination of drinking water
was reported as a risk of bladder cancer. Nitrates are
endogenously reduced to nitrites, which through subse-
quent nitrosation give rise to highly carcinogenic N-
nitroso compounds [4]. Other etiological factors impli-
cated in the development and progression of bladder
cancer includes urinary tract infections (UTIs) including
bacterial, parasitic, fungal, and viral infections; urinary
lithiasis and pelvic radiation [5]. Bacteria are the primary
cause of UTIs, with the vast majority (70–80%) attribu-
ted specifically to infection with E. coli. A recurring* Correspondence: hala_elmosalamy@yahoo.com
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reproduction in any medium, provided the ortheme in the link between bacterial infection and car-
cinogenesis is that of chronic inflammation, which is
often a common feature of persistent infection [6,7].
One of the key molecules that link chronic inflammation
and cancer is represented by the NF-κB family of tran-
scription factors [7]. NF-κB activation induces the ex-
pression of more than 200 genes which have been
shown to suppress apoptosis and induce cellular trans-
formation, proliferation, invasion, metastasis, chemo-re-
sistance, radio-resistance, and/or inflammation [8].
Altered expression of genes involved in suppression of
apoptosis (i.e. Bcl-2 family members and inhibitor of
apoptosis proteins), a key feature of cancer cells, is often
due to deregulated NF-κB activity. The expressions of
numerous cytokines that are growth factors for tumor
cells such as interleukin 1β (IL-1β); tumor necrosis fac-
tor (TNF); epidermal growth factor (EGF) and IL-6 are
also regulated by NF-κB [9]. IL-6 is a major proinflam-
matory cytokine that participates in inflammation-
associated carcinogenesis [10]. Elevated plasma and
urine levels of IL-6 have been demonstrated in cancerntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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study aimed to evaluate the possible role of E. coli infec-
tion during bladder carcinogenesis and the changes in
NF-κB pathway and its related products.
Results
All experimental protocols and procedures were
approved by the Animal Ethics Committee of Cairo Na-
tional Cancer Institute.
Histopathological examination
Bladder histopathological changes are presented in
Figure 1. The histopathological examination revealed
that E. coli infected group was able alone to produce
some histopathological changes in bladder tissue ran-
ging from inflammation to dysplasia and that nitrosa-
mine precursor plus E. coli group showed highest
incidences of urinary bladder lesions than the nitro-
samine precursor group and E. coli group.
NF-κB p65, Bcl-2 and IL-6 levels
Levels of NF-κB p65, Bcl-2 and IL-6 are presented in
Table 1. As indicated in Table 1, at 3 months interval, the
mean±SD of NF-κB p65, Bcl-2 and IL-6 levels were signifi-
cantly higher in the three groups compared with those
obtained in the control group (P< 0.05). In addition a sig-
nificant difference was observed among the three groups,
with those of group IV (receiving nitrosamine precursor
and infected with E. coli) showing the highest values.
Regarding NF-κB p65 levels, there was a significant increase
in group II (0.92±0.22 ng/ml), group III (0.84±0.17 ng/
ml), and group IV (1.19±0.19 ng/ml) compared with the
control group (0.57±0.07 ng/ml). The anti-apoptotic pro-
tein; Bcl-2 level was significantly increased in groups II
(354.74±23.44 U/ml), group III (331.78±11.86 U/ml), and
group IV (387.05±8.40 U/ml) compared with the control
group level (309. 14±14.55 U/ml). Finally for IL-6 level
there was a significant increase in group II (19.76±1.64 pg/
ml), group III (19.21±1.56 pg/ml), and group IV
(24.80±2.20 pg/ml) compared with the control group
(14.09±0.87 pg/ml).
At 6 months interval, the mean ± SD of NF-κB p65,
Bcl-2 and IL-6 levels also showed significant increase in
the three groups compared with those obtained in the
control group. In addition a significant difference was
also observed among the three groups, with those of
group IV (receiving nitrosamine precursor and infected
with E. coli) showing the highest values. Regarding NF-
κB p65 levels, there was a significant increase in group
II (1.11 ± 0.19 ng/ml), group III (1.27 ± 0.20 ng/ml), and
group IV (1.52 ± 0.21 ng/ml) compared with the control
group (0.61 ± 0.08 ng/ml). The anti-apoptotic protein;
Bcl-2 level was significantly increased in groups II
(485.36 ± 60.12 U/ml), group III (361.59 ± 11.95 U/ml),and group IV (544.54 ± 37.11 U/ml) compared with the
control group level (320.61 ± 7.47 U/ml). Finally for IL-6
level there was a significant increase in group II
(23.13 ± 1.46 pg/ml), group III (22.29 ± 1.48 pg/ml), and
group IV (30.66 ± 3.20 pg/ml) compared with the control
group (14.74 ± 1.23 pg/ml).
At 9 months interval, the mean ± SD of NF-κB p65,
Bcl-2 and IL-6 levels were significantly higher in the
three groups compared with those obtained in the con-
trol group. In addition a significant difference was
observed among the three groups, with those of group IV
(receiving nitrosamine precursor and infected with E. coli)
showing the highest values. Regarding NF-κB p65
levels, there was a significant increase in group II
(1.30 ± 0.22 ng/ml), group III (1.66 ± 0.27 ng/ml), and
group IV (1.72 ± 0.14 ng/ml) compared with the con-
trol group (0.70 ± 0.11 ng/ml). The anti-apoptotic pro-
tein; Bcl-2 level was significantly increased in groups II
(485.58 ± 120.36 U/ml), group III (386.92 ± 19.14 U/
ml), and group IV (592.60 ± 75.22 U/ml) compared
with the control group level (323.47 ± 14.33 U/ml). Fi-
nally for IL-6 level there was a significant increase in group
II (26.41±1.89 pg/ml), group III (24.37±1.32 pg/ml), and
group IV (40.55±2.69 pg/ml) compared with the control
group (15.63±0.89 pg/ml).
Discussion
The involvement of bacteria in the process of carcino-
genesis remains controversial [6] because of a lack of
agreement on potential molecular mechanisms.
It was proven that urinary tract infection promotes
carcinogenesis in the urinary tract of the rat and that in-
fection with live E. coli resulted in persistent infection
and diffuses urothelial hyperplasia in addition to acute
and chronic inflammation [12].
In our study; Group IV (nitrosamine precursor plus E.
coli group) showed highest incidences of urinary bladder
lesions than the nitrosamine precursor group; moreover
E. coli group alone was able to produce some histo-
pathological changes in bladder tissue. These findings
suggested that urinary bladder infection by E. coli may
play a major additive and synergistic role in bladder
carcinogenesis.
These results are consistent with the study of Ashmawey
and colleagues [13] who reported that E. coli infection in
the bladder tissues increases the carcinogenic ability of ni-
trosamine precursors. Three mechanisms were suggested
to account for the tumor enhancing effect of E. coli in the
experiment. First, E. coli infection of bladder tissues
increases the carcinogenic ability of nitrosamine precursors
and this may be due to increase of nitrite production by the
bacteria and continuous production of nitrosoamine by
helping in-situ nitrosamine synthesis. Second, E. coli infec-
tion accelerated urothelial proliferation. This may have
Figure 1 (See legend on next page.)
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Figure 1 Histopathological changes in different studied groups; control group (group I), E. coli group (group II), nitrosamine
precursors group (group III), and E. coli and nitrosamine precursors group (IV). (a): Urinary bladder of rat in control group (group I)
showing normal histological structure of the lining mucosal epithelium (m), underlining lamina propria (p) and muscularis (ml). (b): Urinary
bladder of rat in E. coli group (group II) at 3 months showing focal inflammatory cell infiltration (arrow) with sever dilatation of blood vessels in
the lamina propria (c): Urinary bladder of rat in E. coli group (group II) at 6 months showing focal hyperplasia and stratification in the mucosal
epithelium (m). (d): Urinary bladder of rat in E. coli group (group II) at 9 months showing dysplasia in the mucosal lining epithelium (m) with
inflammatory cells infiltration in lamina propia (arrow). (e): Urinary bladder of rat in nitrosamine precursors group (group III) at 3 months showing
dysplasia in the mucosal lining epithelium (d) with degenerative changes (s). (f): Urinary bladder of rat in nitrosamine precursors group (group III)
at 6 months showing dysplasia in the mucosal epithelium (s) with congestion of newly formed blood capillaries in underlining lamina propria
(arrow). (g): Urinary bladder of rat in nitrosamine precursors group (group III) at 9 months showing dysplasia in the lining mucosal epithelium (s).
(h): Urinary bladder of rat in E. coli and nitrosamine precursors group (group IV) at 3 months showing hyperplasia with polyp formation (h) and
degeneration (arrow) in mucosal lining epithelium. (i): Urinary bladder of rat in E. coli and nitrosamine precursors group (group IV) at 6 months
showing degeneration and dysplasia (h) in mucosal lining epithelium with inflammatory cells infiltration (m) in underlying lamina propria. (j):
Urinary bladder of rat in E. coli and nitrosamine precursors group (group IV) at 9 months showing hyperplasia and dysplasia (s) in mucosal lining
epithelium.
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prolonged oxidative and nitrosative stresses which results
in DNA damage and mutation [13].
Our results showed the highest level of NF-κBp65 in E.
coli plus nitrosamine precursor group. In the absence of in-
flammatory stimuli, NF-κB p65 is retained in an inactive
complex in the cytoplasm by the chaperone-like protein in-
hibitor of Kappa B alpha (I-κBα). With exposure to pro-
inflammatory stimuli, such as Toll-like receptors-4 agonist
(TLR4) or pro-inflammatory cytokines, phosphorylation of
I-κB occurs, leading to its degradation and subsequent
release of NF-κB p65 to translocate to the nucleus, driving
inflammatory gene expression [14]. The highest level of
NF-κBp65 in E. coli plus nitrosamine precursor group,
observed in this study is in agreement with [15,16] who
reported that E. coli lipopolysaccharide (LPS), a major cell
wall component of E. coli, treatment induced IκB phosphor-
ylation, IκB degradation, and NF-κB translocation. Also
Saban and colleagues [17] during a study of gene expression
changes occurring in the early stages of genitourinary in-
flammation mediated by LPS reported that NF-κB pathway
genes were up-regulated by LPS stimulation. This can be
explained by the fact that induction of inflammation by LPS
or E. coli in bladder uroepithelial cells involves the TLRs
and CD14. These activate signaling pathways, including
NF-κB and p38 mitogen- activated protein kinase (p38
MAPKs) [18].
Our results showed highest level of Bcl-2 in E. coli
plus nitrosamine precursor group followed by E. coli
group and nitrosamine precursor group respectively.
These results can be explained by the ability of bacterial
pathogens to inhibit apoptosis in eukaryotic cells during
infection as prevention of apoptosis provides a survival
advantage because it enables the bacteria to replicate in-
side host cells [19].
Many pathogens rely on NF-κB activation to inhibit
apoptosis. The Gram-negative bacteria cell surfacecomponent LPS activates the NF-κB pathway during in-
fection [20]. Because NF-κB activation has many pro-
survival effects on the host cell, activation of the NF-κB
pathway by LPS might be a simple explanation of how
most bacteria inhibit apoptosis [19].
The increase in Bcl-2 level in nitrosamine precursor
group observed in our results is in consistent with El
Gendy and colleagues [21] who reported that the levels
of Bcl-2 protein significantly increased over all the peri-
ods of treatment (12 months) in rats receiving nitrosa-
mine precursors compared with the corresponding level
of normal control rats fed with standard diet.
Our results showed highest level of IL-6 in E. coli plus
nitrosamine precursor group followed by E. coli group
and nitrosamine precursor group respectively. E. coli en-
hancing effect on IL-6 production clearly observed in
our study is in agreement with Feng and colleagues [15]
who reported that LPS treatment caused a marked in-
crease in IL-6 production in macrophages.
Neuhaus and colleagues [22] had also shown that IL-6
and IL-6 receptor expression was found in urothelium,
lamina propria and detrusor cells isolated from bladder
biopsies of tumor patients; these researchers further found
that LPS stimulation evoked a time-dependent synthesis
and/or release of IL-6, IL-6 receptor, and transcription fac-
tor signal transducer and activator of transcription 3
(Stat3) in cultured human detrusor smooth muscle cells.
The ability of E. coli to increase IL-6 level can be
explained by activating several signaling pathways, includ-
ing NF-κB and p38MAPKs [18] with subsequent produc-
tion of Il-6.
Conclusion
In conclusion E. coli infection might play a role in the
development of bladder cancer and this effect may be
mediated by activation of NF-κB pathway resulting in in-
hibition of apoptosis and increased inflammation.
Table 1 NF-κBp65 tissue homogenate level (ng/ml), serum level of Bcl-2 (U/ml) and IL-6 (pg/ml)
Group NF-κBp65 (ng/ml) Bcl-2 (U/ml) IL-6 (pg/ml)
3 months 6 months 9 months 3 months 6 months 9 months 3 months 6 months 9 months
Group I Range 0.51- 0.67 0.51-0.75 0.60-0.87 293.30- 331.94 310.74-331.94 305.78- 348.24 12.65-15.20 13.55-16.95 14.5-17.00
Mean ± S.D 0.57 ± 0.07 0.61 ± 0.08 0.70 ± 0.11 309.14 ± 14.55 320.61 ± 7.47 323.47 ± 14.33 14.09 ± 0.87 14.74 ± 1.23 15.63 ± 0.89
Group II Range 0.52-1.13 0.91- 1.145 1.13-1.74 329.75-396.42 412.63-584.94 354.27- 681.57 17.77-22.44 20.91-25.11 24.76-29.69
Mean ± S.D 0.92 ± 0.22a,d 1.11 ± 0.19a,d 1.30 ± 0.22a,c,d 354.74 ± 23.44a,d 485.36 ± 60.12a,c,d 485.58 ± 120.36a 19.76 ± 1.64a,d 23.13 ± 1.46 a,d 26.41 ± 1.89a,d
Group III Range 0.57- 1.05 1.02-1.50 1.39- 2.09 315.83-351.77 341.94-374.09 362.57-407.20 17.22-21.78 20.08-24.22 22.50-25.59
Mean ± S.D 0.84 ± 0.17a,d 1.27 ± 0.20a,d 1.66 ± 0.27a,b 331.78 ± 11.86 a,d 361.59 ± 11.95a,b,d 386.92 ± 19.14a,d 19.21 ± 1.56a,d 22.29 ± 1.48 a,d 24.37 ± 1.32a,d
Group IV Range 0.94- 1.40 1.30-1.87 1.58-1.95 377.06-399.89 484.65-595.49 522.07- 726.57 22.00-27.46 26.61-34.78 35.87-43.51
Mean ± S.D 1.19 ± 0.19a,b,c 1.52 ± 0.21a,b,c 1.72 ± 0.14a,b 387.05 ± 8.40a,b,c 544.54 ± 37.11a,b,c 592.60 ± 75.22a,c 24.80 ± 2.20a,b,c 30.66 ± 3.20a,b,c 40.55 ± 2.69a,b,c
Group I: Control group; Group II: E. coli group; Group III: Nitrosamine precursor group; Group IV: E. coli and nitrosamine precursor; a: Significantly different from control group (group I) at P<0.05; b: Significantly
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Experimental animals and dosing
Ninety five male albino rats, weighing 50–60 gm were
included in the study and divided into four groups; as
follows: group I (Gr I, 20 rats): Normal control fed the
standard diet . Group II (Gr II, 25 rats): E. coli infected;
the rats infected by 0.1 ml saline containing suspension
of E. coli in the bladder (approximately 2 X 10 6 organ-
isms), according to [23]. Group III (Gr III, 25 rats):
Received nitrosamine precursor; dibutyl amine (DBA)
1000 ppm and sodium nitrate 2000 ppm; in drinking
water according to [21]. Group IV (Gr IV, 25 rats):
Received nitrosamine precursor; dibutyl amine (DBA)
1000 ppm and sodium nitrate 2000 ppm; in drinking
water and infected by E. coli in the bladder. At the end
of the experiment, animals were decapitated and 5 ml of
blood was collected. The present experiment was contin-
ued 36 weeks.
Laboratory procedures
At three months interval (3, 6 and 9 months) animals
were sacrificed and bladder tissue was separated and
blood was collected into vacutainer clotted tubes. For
histopathological studies bladder tissue pieces were fixed
in 10% formalin, blocked in paraffin, sectioned, and
stained with hematoxyline and eosin. Finally, the sam-
ples were examined by a pathologist.
Specimens of bladder were removed immediately from
sacrificed animals, washed with saline, dried, cut into
weighed pieces and kept frozen at −80°C, then tissue
homogenate was prepared according to [24] for NF-κB
p65 determination by ELISA kit (Glory Science Co., Ltd,
USA) following the manufacturer instructions.
Sera were obtained by centrifugation at 4000 rpm for
10 minutes. Sera were separated. Aliquoted sera were
kept frozen at −80°C until used for Bcl-2 determination by
ELISA kit (the Calbiochem Laboratories, USA, Cat QIA23)
and IL-6 determination by ELISA kit (IBL, USA, Cat IB39452)
following the manufacturer instructions.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism version 5.01 software package (GraphPad Software,
Inc. CA, USA). Data are presented as mean± standard
deviation (S.D). To determine differences between groups,
analysis of variance (ANOVA) followed by Tukey’s mul-
tiple comparison post hoc analysis was used for multiple
comparisons between different groups. The level of statis-
tical significance was set at probability P≤ 0.05.
Abbreviations
E. coli: Escherichia coli; NF-κBp65: Nuclear factor kappa p65; Bcl-2: B-cell
lymphoma 2; IL-6: Interleukin 6; UTIs: Urinary tract infections; IL-
1β: Interleukin 1β; TNF: Tumor necrosis factor; EGF: Epidermal growth factor;
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